Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022
Operating activities:
Net loss	$ (179,178)	$ (22,820)
Less: Loss from discontinued operations, net of tax	(74,429)	(681)
Loss from continuing operations	(104,749)	(22,139)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization	31,073	24,863
Provision for expected credit losses	640	2,505
Equity based compensation	(886)	9,505
Change in fair value of contingent consideration	527	542
Change in fair value of interest rate swap	0	(4,196)
Deferred income taxes	(3,540)	(27,698)
Impairment of assets	78,615	0
Loss on disposal of a business	977	0
Unrealized loss on foreign currency fluctuations	601	1,020
Other, net	1,139	408
Changes in operating assets and liabilities:
Accounts receivable	11,329	(21,157)
Inventories	(13,074)	(2,614)
Accounts payable and accrued expenses	14,765	17,747
Other current and noncurrent assets and liabilities	(1,963)	3,134
Net cash from operating activities - continuing operations	15,454	(18,080)
Net cash from operating activities - discontinued operations	(2,169)	0
Net cash from operating activities	13,285	(18,080)
Investing activities:
Proceeds from sale of a business	34,897	0
Investment held in trust for the acquisition of CartiHeal	0	(50,000)
Acquisitions, net of cash acquired	0	(231)
Purchase of property and equipment	(4,957)	(4,990)
Investments and acquisition of distribution rights	0	(1,478)
Net cash from investing activities - continuing operations	29,940	(56,699)
Net cash from investing activities - discontinued operations	(11,506)	0
Net cash from investing activities	18,434	(56,699)
Financing activities:
Proceeds from issuance of Class A and B common stock	223	4,257
Tax withholdings on equity-based compensation	0	(3,352)
Borrowing on revolver	49,000	25,000
Payment on revolver	(42,000)	0
Debt refinancing costs	(3,661)	0
Payments on long-term debt	(38,264)	(9,019)
Other, net	(166)	(26)
Net cash from financing activities	(34,868)	16,860
Effect of exchange rate changes on cash	701	(293)
Net change in cash, cash equivalents and restricted cash	(2,448)	(58,212)
Cash, cash equivalents and restricted cash at the beginning of the period	31,837	99,213
Cash, cash equivalents and restricted cash at the end of the period	29,389	41,001
Supplemental disclosure of noncash investing and financing activities
Accrued liabilities for intellectual property	709	0
Accounts payable for purchase of property, plant and equipment	$ 968	$ 67